Immix Biopharma, Inc. $IMMX Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC boosted its holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) by 22.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,802,002 shares of the company’s stock after acquiring an additional 880,434 shares during the quarter. Janus Henderson Group PLC owned about 0.09% of Immix Biopharma worth $43,698,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IMMX. The Manufacturers Life Insurance Company purchased a new stake in shares of Immix Biopharma during the 1st quarter worth $264,000. Sei Investments Co. increased its holdings in shares of Immix Biopharma by 100.0% in the 1st quarter. Sei Investments Co. now owns 147,140 shares of the company’s stock valued at $1,340,000 after purchasing an additional 73,570 shares in the last quarter. LGT Fund Management Co Ltd. lifted its stake in shares of Immix Biopharma by 233.3% in the first quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock valued at $3,795,000 after purchasing an additional 291,594 shares during the period. Private Advisor Group LLC lifted its stake in shares of Immix Biopharma by 9.5% in the first quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock valued at $316,000 after purchasing an additional 3,000 shares during the period. Finally, Kera Capital Partners Inc. acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at about $68,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Price Performance

Immix Biopharma stock opened at $8.32 on Monday. Immix Biopharma, Inc. has a 52 week low of $1.94 and a 52 week high of $12.14. The firm’s 50-day simple moving average is $9.33 and its 200 day simple moving average is $8.69. The firm has a market capitalization of $452.69 million, a PE ratio of -9.04 and a beta of 0.11.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, research analysts expect that Immix Biopharma, Inc. will post -0.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IMMX. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Needham & Company LLC assumed coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $21.00 price target for the company. Citigroup began coverage on Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating on the stock. Lifesci Capital assumed coverage on Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price target on the stock. Finally, HC Wainwright raised their price objective on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.71.

Immix Biopharma Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.